Rafael Martinez
Family Medicine · San Antonio, TXNPI 1942217278
Payments from drug & device makers
Across 179 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Viiv Healthcare Company$743
- Johnson & Johnson$351
- Merck$222
- AbbVie$167
- Napo Pharmaceuticals Inc$109
- plus $360 from 9 others
What the payments were for
- Speaking & faculty fees$161%
- Food & beverage$3,01296%
- Education$1144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 69 | $1,190 |
| Viiv Healthcare Company | 35 | $743 |
| Johnson & Johnson | 27 | $351 |
| Merck | 16 | $222 |
| AbbVie | 10 | $167 |
| Napo Pharmaceuticals Inc | 6 | $109 |
| Janssen Products, LP | 1 | $99 |
| Theratechnologies Inc. | 5 | $88 |
| Antares Pharma, Inc. | 3 | $43 |
| Sanofi | 1 | $37 |
| Janssen Scientific Affairs, LLC | 2 | $30 |
| GSK | 1 | $22 |
| EMD Serono, Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
How this compares
$3,142 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 942 | $3,754,861 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 268 | $1,073,300 |
| TivicayDolutegravir Sodium | 187 | $517,587 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 111 | $504,259 |
| JulucaDolutegravir/Rilpivirine | 122 | $453,132 |
| DescovyEmtricitabine/Tenofov Alafenam | 188 | $416,599 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 73 | $258,680 |
| PifeltroDoravirine | 131 | $227,354 |
| PrezcobixDarunavir/Cobicistat | 73 | $181,176 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 46 | $166,631 |
| DovatoDolutegravir Sodium/Lamivudine | 52 | $161,183 |
| MounjaroTirzepatide | 133 | $139,065 |
| Darunavir | 77 | $108,480 |
| OzempicSemaglutide | 98 | $97,795 |
| EnbrelEtanercept | 13 | $97,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,190 | $5,244,7611,398 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Triumeq, Dovato | $743 | $1,390,582434 claims |
| Janssen Products, LPSymtuza | $99 | $504,259111 claims |
| MerckPifeltro, Isentress, Januvia | $222 | $375,068247 claims |
| Johnson & JohnsonPrezcobix | $351 | $181,17673 claims |
| AbbVieCreon, Linzess | $167 | $67,68049 claims |
| PfizerEliquis | $13 | $12,35019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Douglas DenhamSan Antonio$68.5M
- George AtieeSan Antonio$19.9M
- Leonel ReyesSan Antonio$4.3M
- Brian MacgillivraySan Antonio$3.2M
- Juan GarzaSan Antonio$2.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.